Quarterly report pursuant to Section 13 or 15(d)

INVESTMENT (Details Narrative)

v3.23.3
INVESTMENT (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
ILiAD Biotechnologies, LLC [Member]          
Schedule of Equity Method Investments [Line Items]          
Aggregrate investment $ 7,000,000   $ 7,000,000    
Book value of the investment $ 5,144,000   $ 5,144,000    
Iliad [Member] | Class C Units [Member]          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage not fully diluted 6.80%   6.80%    
Iliad [Member]          
Schedule of Equity Method Investments [Line Items]          
Aggregrate investment $ 7,000,000   $ 7,000,000    
Equity investment net loss 532,000 $ 285,000 1,597,000 $ 1,073,000  
ILiAD additional comprehensive loss         $ 621,000
Allocated share of additional loss $ 42,000   $ 42,000    
Iliad [Member] | Class C Units [Member]          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage fully diluted     6.10%